

# Peter John Roberts-Thomson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4469164/publications.pdf>

Version: 2024-02-01

146  
papers

4,261  
citations

81889

39  
h-index

138468

58  
g-index

149  
all docs

149  
docs citations

149  
times ranked

3440  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of cancer in patients with scleroderma: a population based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 728-731.	0.9	179
2	Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 1400-1408.	6.7	155
3	Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. <i>British Journal of Rheumatology</i> , 2003, 42, 123-134.	2.3	131
4	Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 149-156.	0.9	112
5	Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis, and the effects of methylprednisolone. <i>Arthritis and Rheumatism</i> , 1996, 39, 216-225.	6.7	110
6	Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. <i>Gastroenterology</i> , 1984, 87, 922-926.	1.3	107
7	Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression. <i>Arthritis and Rheumatism</i> , 1996, 39, 1970-1979.	6.7	104
8	Diurnal variation of lymphocyte subsets identified by monoclonal antibodies.. <i>BMJ: British Medical Journal</i> , 1983, 286, 1171-1172.	2.3	100
9	Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis. <i>Arthritis and Rheumatology</i> , 2015, 67, 3234-3244.	5.6	85
10	A randomized placebo-controlled trial of arthroscopic lavage versus lavage plus intra-articular corticosteroids in the management of symptomatic osteoarthritis of the knee. <i>British Journal of Rheumatology</i> , 2003, 42, 1477-1485.	2.3	84
11	South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. <i>International Journal of Rheumatic Diseases</i> , 2012, 15, 102-109.	1.9	83
12	Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. <i>Internal Medicine Journal</i> , 2001, 31, 220-229.	0.8	80
13	Clinical heterogeneity and prognostic features of South Australian patients with anti- $\epsilon$ -synthetase autoantibodies. <i>Internal Medicine Journal</i> , 2011, 41, 674-679.	0.8	77
14	Unconventional Remedies Used for Patients With Juvenile Arthritis. <i>Pediatrics</i> , 1990, 85, 150-154.	2.1	77
15	Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. <i>Postgraduate Medical Journal</i> , 2010, 86, 79-82.	1.8	66
16	Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. <i>Rheumatology</i> , 2010, 49, 862-875.	1.9	66
17	The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. <i>Rheumatology International</i> , 2013, 33, 965-971.	3.0	66
18	Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. <i>Internal Medicine Journal</i> , 2003, 33, 216-220.	0.8	65

#	ARTICLE	IF	CITATIONS
19	Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 331-338.	1.9	65
20	Isolated pulmonary hypertension in scleroderma. <i>Internal Medicine Journal</i> , 2005, 35, 28-33.	0.8	63
21	Risk factors for lung cancer in patients with scleroderma: a nested case-control study. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 551-553.	0.9	63
22	Effects of intraarticular glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: Findings in a double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2001, 44, 343-350.	6.7	62
23	Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1558-1564.	0.9	60
24	Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus. <i>International Journal of Rheumatic Diseases</i> , 2010, 13, 132-137.	1.9	59
25	Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 992-999.	0.9	57
26	Survival in scleroderma: results from the population-based South Australian Register. <i>Internal Medicine Journal</i> , 2011, 41, 381-390.	0.8	57
27	Epidemiology of biopsy-proven giant cell arteritis in South Australia. <i>Internal Medicine Journal</i> , 2014, 44, 32-39.	0.8	56
28	Effects of ex vivo manipulation on the expression of cell adhesion molecules on neutrophils. <i>Journal of Immunological Methods</i> , 1995, 186, 217-224.	1.4	55
29	A Multilaboratory Peer Assessment Quality Assurance Program-Based Evaluation of Anticardiolipin Antibody, and beta2-Glycoprotein I Antibody Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 73-84.	2.7	55
30	Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part I—Anticardiolipin and Anti-β2-Glycoprotein I Antibodies. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 390-403.	2.7	54
31	Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. <i>Internal Medicine Journal</i> , 2012, 42, 191-198.	0.8	49
32	Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study. <i>Journal of Rheumatology</i> , 2011, 38, 2215-2217.	2.0	47
33	Direct activation of neutrophil chemiluminescence by rheumatoid sera and synovial fluid.. <i>Annals of the Rheumatic Diseases</i> , 1983, 42, 158-162.	0.9	46
34	High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. <i>European Journal of Clinical Pharmacology</i> , 1992, 42, 85-88.	1.9	46
35	Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features. <i>International Journal of Rheumatic Diseases</i> , 2010, 13, 117-124.	1.9	46
36	Necrotizing myopathy: Clinicoserologic associations. <i>Muscle and Nerve</i> , 2012, 45, 189-194.	2.2	45

#	ARTICLE	IF	CITATIONS
37	Rheumatic manifestations of infective endocarditis. <i>Rheumatology International</i> , 1992, 12, 61-63.	3.0	44
38	A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 688-694.	0.5	44
39	Immunohistochemical analysis of synovial membranes from inflammatory and non-inflammatory arthritides: scarcity of CD5 positive B cells and IL2 receptor bearing T cells. <i>Pathology</i> , 1992, 24, 19-26.	0.6	41
40	Bee€esting mortality in Australia. <i>Medical Journal of Australia</i> , 1984, 140, 209-211.	1.7	40
41	Scleroderma in South Australia: further epidemiological observations supporting a stochastic explanation. <i>Internal Medicine Journal</i> , 2006, 36, 489-497.	0.8	39
42	Relationship between Paraprotein Polymerization and Clinical Features in IgA Myeloma. <i>British Journal of Haematology</i> , 1976, 33, 117-130.	2.5	36
43	Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression. <i>Rheumatology</i> , 2001, 40, 965-977.	1.9	33
44	Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease€modifying antirheumatic drug treatment and correlation with radiologic outcome. <i>Arthritis and Rheumatism</i> , 2008, 59, 911-920.	6.7	33
45	Cerebrospinal fluid immunoglobulin quotients, kappa/lambda ratios, and viral antibody titres in neurological disease.. <i>Journal of Clinical Pathology</i> , 1976, 29, 1105-1115.	2.0	31
46	Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone?. <i>Annals of the Rheumatic Diseases</i> , 1988, 47, 28-33.	0.9	31
47	Rheumatic disease and the Australian Aborigine. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 266-270.	0.9	31
48	A Review of Î²2-Glycoprotein-I Antibody Testing Results From a Peer-Driven Multilaboratory Quality Assurance Program. <i>American Journal of Clinical Pathology</i> , 2007, 127, 441-448.	0.7	31
49	Lymphocyte surface marker expression in rheumatic diseases: evidence for prior activation of lymphocytes in vivo.. <i>Annals of the Rheumatic Diseases</i> , 1990, 49, 81-87.	0.9	30
50	Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study. <i>Rheumatology International</i> , 2008, 28, 895-899.	3.0	30
51	Factors relating to circulating immune complexes in rheumatoid arthirits.. <i>Annals of the Rheumatic Diseases</i> , 1976, 35, 314-320.	0.9	29
52	Paraproteinemic Crystalloidal Keratopathy: An Ultrastructural Study of Two Cases, Including Immunoelectron Microscopy. <i>Ultrastructural Pathology</i> , 1993, 17, 643-668.	0.9	29
53	Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis. <i>Pathology</i> , 2005, 37, 220-225.	0.6	28
54	The In Vitro Activation of Complement by Radiologic Contrast Materials and its Inhibition with ??-Aminocaproic Acid. <i>Investigative Radiology</i> , 1981, 16, 152-158.	6.2	26

#	ARTICLE	IF	CITATIONS
55	Neutrophil activation by immune complexes and the role of rheumatoid factor.. Annals of the Rheumatic Diseases, 1984, 43, 34-39.	0.9	26
56	The subcutaneous air pouch model of synovium and the inflammatory response to heat aggregated gammaglobulin. Agents and Actions, 1986, 18, 421-428.	0.7	26
57	Idiopathic inflammatory myopathies. Internal Medicine Journal, 2009, 39, 179-190.	0.8	26
58	Polymeric IgA myeloma, hyperlipidaemia and xanthomatosis: a further case and review. Postgraduate Medical Journal, 1975, 51, 44-51.	1.8	25
59	Low molecular weight IgM in rheumatoid arthritis and other rheumatic diseases. Arthritis and Rheumatism, 1981, 24, 795-802.	6.7	25
60	Quantitation of rheumatoid factor by laser nephelometry. Rheumatology International, 1982, 2, 17-20.	3.0	25
61	IgG and IgM anti-endothelial cell antibodies in patients with collagen-vascular disorders. Rheumatology International, 1990, 10, 113-119.	3.0	25
62	Methylprednisolone infusion therapy in rheumatoid arthritis patients. The effect on synovial fluid lymphocyte subsets and inflammatory indices. Arthritis and Rheumatism, 1986, 29, 32-38.	6.7	24
63	Studies on the interaction of rheumatoid factor with monosodium urate crystals and case report of coexistent tophaceous gout and rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1985, 44, 384-389.	0.9	23
64	Routine quantification of rheumatoid factor by rate nephelometry.. Annals of the Rheumatic Diseases, 1985, 44, 379-383.	0.9	23
65	ADULT ONSET STILL'S DISEASE OR COXSACKIE POLYARTHRITIS?. Australian and New Zealand Journal of Medicine, 1986, 16, 509-511.	0.5	23
66	Evaluation of CD5-positive B cells in blood and synovial fluid of patients with rheumatic diseases. Rheumatology International, 1987, 7, 255-259.	3.0	23
67	The use of the hand anatomic index to assess deformity and impaired function in systemic sclerosis. Rheumatology International, 2006, 26, 439-444.	3.0	23
68	Risk of cancer in patients with biopsy-proven giant cell arteritis. Rheumatology, 2010, 49, 756-759.	1.9	23
69	The effects of pulse methylprednisolone on matrix metalloproteinase and tissue inhibitor of metalloproteinaseâ€1 expression in rheumatoid arthritis. Rheumatology, 2000, 39, 1067-1073.	1.9	21
70	Prevalence of sicca symptoms in a South Australian cohort with systemic sclerosis. Internal Medicine Journal, 2008, 38, 897-903.	0.8	21
71	Wegenerâ€™s granulomatosis: epidemiological and clinical features in a South Australian study. Internal Medicine Journal, 2008, 38, 776-780.	0.8	21
72	Molecular size heterogeneity of immunoglobulins in health and disease. Clinical and Experimental Immunology, 2008, 79, 328-334.	2.6	20

#	ARTICLE	IF	CITATIONS
73	Antinuclear antibody testing in a regional immunopathology laboratory. <i>Immunology and Cell Biology</i> , 2003, 81, 409-412.	2.3	18
74	Cigarette smoking in patients with systemic sclerosis reduces overall survival: Comment on the article by Hudson et al. <i>Arthritis and Rheumatism</i> , 2011, 63, 1758-1759.	6.7	18
75	Circulating and intra-articular immune complexes in rheumatoid arthritis: a comparative study of the C1q binding and monoclonal rheumatoid factor assays.. <i>Annals of the Rheumatic Diseases</i> , 1980, 39, 438-444.	0.9	17
76	Autoantibodies in patients with juvenile chronic arthritis and their immediate family relatives.. <i>Annals of the Rheumatic Diseases</i> , 1990, 49, 968-972.	0.9	17
77	Methotrexate hepatotoxicity: What is the evidence?. <i>Inflammation Research</i> , 1998, 47, 148-151.	4.0	17
78	IgM paraproteinaemia: disease associations and laboratory features. <i>Pathology</i> , 2002, 34, 356-361.	0.6	17
79	A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis. <i>Rheumatology International</i> , 2012, 32, 611-619.	3.0	17
80	A simple one-step procedure for preparation of C1-deficient human serum. <i>Journal of Immunological Methods</i> , 1984, 69, 277-280.	1.4	16
81	Low molecular weight IgM. <i>Journal of Immunological Methods</i> , 1986, 88, 97-100.	1.4	16
82	South australian scleroderma register: Analysis of deceased patients. <i>Pathology</i> , 1998, 30, 386-390.	0.6	16
83	Does steroid pulsing influence the efficacy and toxicity of chrysotherapy? A double blind, placebo controlled study.. <i>Annals of the Rheumatic Diseases</i> , 1990, 49, 370-372.	0.9	15
84	Scleroderma: it has been a long hard journey. <i>Internal Medicine Journal</i> , 2006, 36, 519-523.	0.8	15
85	Detection of autoantibodies to ribosomal P protein using recombinant autoantigen in a quantitative immunoassay. <i>Rheumatology International</i> , 1990, 10, 99-102.	3.0	14
86	Adrenaline and anaphylaxis. <i>Medical Journal of Australia</i> , 1985, 142, 708-708.	1.7	13
87	Quantitation and evaluation of low molecular weight IgM in rheumatoid arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1980, 39, 349-353.	0.9	12
88	Illness behaviour in patients with arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1995, 54, 245-250.	0.9	12
89	Impaired delayed type cutaneous hypersensitivity in rheumatoid arthritis reversed by chrysotherapy.. <i>Annals of the Rheumatic Diseases</i> , 1989, 48, 108-113.	0.9	10
90	Anti-Ro52 antibodies, antisynthetase antibodies, and antisynthetase syndrome. <i>Clinical Rheumatology</i> , 2008, 27, 521-523.	2.2	10

#	ARTICLE	IF	CITATIONS
91	Utility of the HEp-2000 antinuclear antibody substrate. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e67-e67.	0.9	10
92	An enhanced chemiluminescence detection system combined with a modified immunoblot technique for the detection of low molecular weight IgM in sera from healthy adults and neonates. <i>Journal of Immunological Methods</i> , 1992, 146, 241-247.	1.4	9
93	In vitro synthesis of low molecular weight IgM in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1985, 28, 112-117.	6.7	8
94	Low molecular weight IgM and CD5 B lymphocytes in rheumatoid arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1994, 53, 383-390.	0.9	8
95	Shared rheumatoid epitope as a risk factor in determining outcome in rheumatoid arthritis. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 234-238.	0.5	8
96	The epidemiology of dermatomyositis in South Australia. <i>APLAR Journal of Rheumatology</i> , 2007, 10, 94-100.	0.2	8
97	A seminal monograph: Mackay and Burnet's Autoimmune diseases. <i>Medical Journal of Australia</i> , 2012, 196, 74-76.	1.7	8
98	Stochastic processes in the aetiopathogenesis of scleroderma. <i>Internal Medicine Journal</i> , 2012, 42, 235-242.	0.8	8
99	Effects of chrysotherapy on circulating lymphocyte numbers and subsets.. <i>Annals of the Rheumatic Diseases</i> , 1988, 47, 15-17.	0.9	7
100	Low molecular weight IgM in primary biliary cirrhosis.. <i>Gut</i> , 1990, 31, 88-91.	12.1	7
101	Sera from patients with systemic lupus erythematosus demonstrate enhanced IgG binding to endothelial cells pretreated with tumour necrosis factor alpha. <i>Rheumatology International</i> , 1995, 15, 99-105.	3.0	7
102	The clinical features of dermatomyositis in a South Australian population. <i>APLAR Journal of Rheumatology</i> , 2007, 10, 86-93.	0.2	7
103	A modified hand anatomic index to assess hand deformity in scleroderma. <i>Rheumatology International</i> , 2009, 29, 847-848.	3.0	7
104	LOW MOLECULAR WEIGHT IgM IN B CELL LYMPHOPROLIFERATIVE DISORDERS. <i>Australian and New Zealand Journal of Medicine</i> , 1984, 14, 121-125.	0.5	6
105	Clinical associations of anti- $\epsilon$ amin autoantibodies. <i>Australian and New Zealand Journal of Medicine</i> , 1996, 26, 162-166.	0.5	6
106	Scleroderma in Australian Aborigines. <i>Internal Medicine Journal</i> , 2005, 35, 60-62.	0.8	6
107	Systemic sclerosis, birth order and parity. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 557-561.	1.9	6
108	The role of nailfold capillary dropout on mortality in systemic sclerosis. <i>Internal Medicine Journal</i> , 2018, 48, 517-523.	0.8	6

#	ARTICLE	IF	CITATIONS
109	SEROLOGICAL INVESTIGATIONS IN THE DIAGNOSIS AND MANAGEMENT OF INFECTIVE ENDOCARDITIS. Australian and New Zealand Journal of Medicine, 1986, 16, 761-765.	0.5	5
110	Rheumatoid arthritis and Australian Aborigines. Medical Journal of Australia, 1998, 168, 92-92.	1.7	5
111	Quantitative and qualitative assessment of hand function and deformity in systemic sclerosis. Rheumatology International, 2007, 27, 509-510.	3.0	5
112	Inflammatory Arthritis in a Patient with Primary Biliary Cirrhosis: B Cell Mediated Synovitis. Journal of Rheumatology, 2010, 37, 212-214.	2.0	5
113	Quality assurance of immunodiagnostic tests in australasia. Pathology, 1991, 23, 125-129.	0.6	5
114	Low molecular weight IgM in the sera of patients with chronic lymphocytic leukemia. Pathology, 1993, 25, 52-56.	0.6	5
115	LIFE THREATENING CARDIAC TAMPONADE COMPLICATING A CASE OF SERONEGATIVE RHEUMATOID ARTHRITIS. Australian and New Zealand Journal of Medicine, 1984, 14, 56-58.	0.5	4
116	Lack of correlation between in vitro and in vivo effects of low density lipoprotein on the inflammatory activity of monosodium urate crystals.. Annals of the Rheumatic Diseases, 1986, 45, 673-676.	0.9	4
117	The clinical associations of mitotic spindle autoantibodies in a South Australian cohort. Australian and New Zealand Journal of Medicine, 1999, 29, 713-717.	0.5	4
118	The role of intravenous methylprednisolone pulses in the management of rheumatoid arthritis. Rheumatology, 2000, 39, 1296-1297.	1.9	4
119	Improving life expectancy of patients with scleroderma: results from the South Australian Scleroderma Register. Internal Medicine Journal, 2018, 48, 951-956.	0.8	4
120	Does rheumatoid arthritis exist in the indigenous Australian Aboriginal population?. Medical Journal of Australia, 1995, 163, 444-445.	1.7	4
121	Preliminary evidence for the presence of an inhibitor on the surface of natural monosodium urate crystals. Arthritis and Rheumatism, 1986, 29, 1172-1173.	6.7	3
122	Low molecular weight IgM in juvenile chronic arthritis.. Archives of Disease in Childhood, 1988, 63, 1453-1456.	1.9	3
123	Frequency and role of low molecular weight IgM in systemic lupus erythematosus. Rheumatology International, 1990, 10, 95-98.	3.0	3
124	Similar effects of pulse corticosteroid and tumor necrosis factor ? blockade in rheumatoid arthritis: Comment on the article by Taylor et al. Arthritis and Rheumatism, 2001, 44, 245-245.	6.7	3
125	Bilateral symmetric gluteal muscle metastases from pancreatic carcinoma presenting as a myositis. Journal of Medical Imaging and Radiation Oncology, 2007, 51, B119-21.	0.6	3
126	Familial scleroderma: nature, nurture or both?. Internal Medicine Journal, 2008, 38, 235-242.	0.8	3



#	ARTICLE	IF	CITATIONS
127	Scleroderma renal crisis: observations from the South Australian Scleroderma Register. Internal Medicine Journal, 2021, 51, 235-242.	0.8	3
128	Large quantities of low molecular weight IgM in mixed cryoglobulinaemia.. Annals of the Rheumatic Diseases, 1988, 47, 105-109.	0.9	2
129	Low molecular weight IgM in healthy adults: Influence of HLA. Human Immunology, 1996, 51, 55-59.	2.4	2
130	Skinprick test sensitivity to olive pollen. Medical Journal of Australia, 1996, 165, 460-460.	1.7	2
131	Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor ? therapy in rheumatoid arthritis. Arthritis and Rheumatism, 1998, 41, 564-565.	6.7	2
132	Microchimerism in systemic sclerosis: Comment on the article by Johnson et al. Arthritis and Rheumatism, 2002, 46, 2538-2538.	6.7	2
133	Proficiency testing in immunopathology: establishing the homogeneity of test material. Pathology, 2005, 37, 164-168.	0.6	2
134	Monozygotic twins with distinct forms of idiopathic inflammatory myositis. Rheumatology, 2009, 48, 855-857.	1.9	2
135	Levels of soluble adhesion molecules and their associations in inflammatory myositis. International Journal of Rheumatic Diseases, 2013, 16, 99-101.	1.9	2
136	Frequency of low molecular weight IgM in human cord blood. Journal of Reproductive Immunology, 1987, 11, 321-325.	1.9	1
137	Anti-Cytoskeletal Antibodies. Autoimmunity, 1991, 11, 129-129.	2.6	1
138	Skinprick test sensitivity to olive pollen. Medical Journal of Australia, 1996, 165, 352-352.	1.7	1
139	Skinprick test sensitivity to olive pollen: In reply. Medical Journal of Australia, 1997, 166, 279-280.	1.7	1
140	A descriptive account of sequential nailfold capillaroscopy in scleroderma. Pathology, 2019, 51, 669-672.	0.6	1
141	Cytokines and cell adhesion molecules in musculoskeletal disorders. Drugs of Today, 1999, 35, 127.	1.1	1
142	Paraproteins: a regional South Australian experience. Asian Pacific Journal of Allergy and Immunology, 2002, 20, 187-95.	0.4	1
143	Methylprednisolone pulse therapy in rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1987, 46, 878-879.	0.9	0
144	Clinical utility of the flow cytometric technique for shared rheumatoid epitope. Rheumatology International, 1999, 19, 31-34.	3.0	0

#	ARTICLE	IF	CITATIONS
145	Letter to the Editor. Rheumatology International, 2007, 28, 197-198.	3.0	0
146	Diagnostic utility of unidentified precipitin lines (UPLs) in immune precipitation assays. Pathology, 2015, 47, 62-67.	0.6	0